Semaglutide improves fatty liver disease and inflammation in people with HIV
Women with HIV need tailored advice on statins and heart disease risk
Progress in reducing new HIV diagnoses much slower for Black men in the US
The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance become a problem?
Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment
HIV medication dolutegravir not linked with increased blood pressure during pregnancy
Switch to an integrase inhibitor leads to greater weight during and after the menopause
Huge increase in PrEP uptake when services offer choice, flexibility and injectable PrEP, African study shows
Far fewer HIV infections in Australian PrEP users – consistent use is key
Some children who start antiretrovirals very early may control HIV after stopping treatment
Prostate cancer diagnosed later in US men with HIV
People-centred blood pressure management improves blood pressure in people with HIV
Six-country African PrEP study achieves high levels of persistence and good adherence in young women
Islatravir plus lenacapavir could be the first once-weekly oral HIV treatment
Broadly neutralising antibodies may be partners for long-acting antiretrovirals
HIV diagnoses continue to fall in US states with high PrEP coverage, while others are left behind
Once-weekly antiretrovirals on the horizon
If one antibody won’t work, how about three? Or three in one?
